Pasithea Therapeutics Corp. (KTTAW) Cash from Operations (2021 - 2026)

Pasithea Therapeutics has disclosed Cash from Operations across 6 years of filings, most recently posting -$4.7 million for Q2 2026.

• In Q2 2026, Cash from Operations fell 21.68% year-over-year to -$4.7 million; the TTM figure through Jun 2026 stood at -$17.8 million (down 42.39% YoY), while the FY2025 annual figure was -$15.2 million, down 9.25% from the prior year.
• Cash from Operations came in at -$4.7 million for Q2 2026 at Pasithea Therapeutics, up from -$4.8 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of -$1.9 million in Q2 2022 to a low of -$5.4 million in Q4 2025.
• Average Cash from Operations over 5 years is -$3.5 million, with a median of -$3.2 million recorded in 2023.
• Year-over-year, Cash from Operations tumbled 742.68% in 2022 and rose 29.94% in 2023.
• Over 5 years, Cash from Operations stood at -$3.2 million in 2022, then slipped by 3.42% to -$3.3 million in 2023, then grew by 25.84% to -$2.4 million in 2024, then tumbled by 120.91% to -$5.4 million in 2025, then climbed by 12.77% to -$4.7 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$4.7 million in Q2 2026, -$4.8 million in Q1 2026, and -$5.4 million in Q4 2025.